FrançaisAre analysts right about NeoGenomics Laboratories, Inc. (NEO)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For NeoGenomics Laboratories, Inc., we replayed every analyst price target of the past 12 months and measured the real outcome: 45% were profitable, average return +9% (111 calls). At 3 months: +1% average return (43% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Needham | 28 | 36% | +8% |
| Raymond James | 12 | 75% | +19% |
| Benchmark | 9 | 44% | -1% |
| Piper Sandler | 9 | 44% | +37% |
| BTIG | 8 | 50% | +28% |
Frequently asked questions
Is NeoGenomics Laboratories, Inc. a buy right now?
The analyst consensus on NeoGenomics Laboratories, Inc. (NEO) is "Buy" (11 bullish, 0 bearish calls over 12 months). This is not advice: historically, 45% of their targets on this stock turned out profitable over 1 year.
What is NeoGenomics Laboratories, Inc.'s price target?
The median 12-month price target is $17.50 (-6% vs $18.64), ranging from $14.00 to $25.00 (4 analysts).
Are analysts accurate on NeoGenomics Laboratories, Inc.?
Over 1 year, 45% of analyst targets on NeoGenomics Laboratories, Inc. were profitable, for an average return of +9% (across 111 timestamped calls). This is JPI Invest's accuracy metric.
What is the NeoGenomics Laboratories, Inc. stock forecast?
Analysts target a median of $17.50 within 12 months, i.e. -6% vs the current price. The most bullish targets $25.00, the most cautious $14.00.
What is the NeoGenomics Laboratories, Inc. stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $17.50, -6%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (45%), and the stock's past trajectory.
Is NeoGenomics Laboratories, Inc. overvalued?
Detailed valuation data for NeoGenomics Laboratories, Inc. is available in the interactive analysis.
📊 See the full interactive analysis of NeoGenomics Laboratories, Inc. →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.